Home › Activist investors › Clearline Capital
Campaign activist. Positions and campaigns from Clearline Capital’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| Heron Therapeutics, Inc. | 5.81%11,026,633 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 5, 2026 | Nov 14, 2018 | Decreased Nov 16, 2026 | ▼ 0.19 pts | Decreased | 13F: none stated |
| Douglas Elliman Inc. | 5.16%4,687,915 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | Feb 14, 2024 | Increased Nov 16, 2026 | ▲ 0.79 pts | Increased | 13F: none stated |
| Xperi Inc. | 4.90%2,391,827 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 | Feb 14, 2023 | Decreased Nov 16, 2026 | ▼ 0.18 pts | Decreased | 13F: none stated |
| Core Scientific, Inc. | 2.30%7,422,853 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Feb 14, 2025 | Increased Nov 16, 2026 | ▲ 1.07 pts | Increased | 13F: none stated |
| Acuren Corporation | 1.56%3,411,687 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | May 16, 2025 | Decreased Nov 16, 2026 | ▼ 0.23 pts | Decreased | 13F: none stated |
| MediaAlpha, Inc. | 1.55%867,018 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | Aug 15, 2023 | Decreased Nov 16, 2026 | ▼ 3.31 pts | Decreased | 13F: none stated |
| Alkami Technology, Inc. | 1.35%1,440,429 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 30, 2026 | May 15, 2026 | Increased Nov 16, 2026 | ▲ 0.92 pts | Increased | 13F: none stated |
| Therapeuticsmd, Inc. | 5.49%635,222 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 9, 2026 | Feb 14, 2017 | — | 0.00 pts | — | 13F: none stated |
| Magnera Corporation | 2.07%741,096 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 | Feb 14, 2025 | — | 0.00 pts | — | 13F: none stated |
| NCR Voyix Corp. | 2.05%2,786,147 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 | Feb 17, 2015 | — | ▲ 0.05 pts | — | 13F: none stated |
| Rogers Corporation | 1.97%350,202 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 23, 2026 | Nov 14, 2024 | — | ▲ 0.02 pts | — | 13F: none stated |
| Blackbaud, Inc. | 1.53%688,846 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 | Nov 14, 2022 | — | ▲ 0.01 pts | — | 13F: none stated |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Heron Therapeutics, Inc. | Settled (agreement with the company) | Jul 24, 2023 | Jul 24, 2023 | — | latest (1) | — |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Heron Therapeutics, Inc. | Settlement | agreement with the company | Jul 24, 2023 | Jul 24, 2023 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 0 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.
“…he other parties thereto (a copy of which has been filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 23, 2023), with respect to the standstill provision that would have prevented the aggregate beneficial ownership of Velan and Rubric from exceeding 15.0% of the Company’s outstanding voting securities.” 8-K, Jul 24, 2023
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Clearline Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| JANA Partners | Schedule 13D | Apr 1, 2026 | 5.0% |
| North Reef Capital Management LP | Schedule 13G | May 15, 2026 | 7.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Sir Martin E. Franklin | Schedule 13D | Feb 14, 2025 | 16.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Engine Capital, L.P. | Schedule 13D | Nov 21, 2024 | — |
| Engine Capital | 13F | Feb 14, 2025 | 6.3% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| The Vanguard Group | Schedule 13G | Jan 30, 2025 | 6.9% |
| Tospring Technology Limited | Schedule 13G | Feb 13, 2025 | 1.9% |
| Jericho Capital | 13F | Feb 14, 2025 | 7.1% |
| BlackRock, Inc. | Schedule 13G | Jul 16, 2025 | 7.8% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| White Mountains Insurance Group LTD | Schedule 13D | Jun 30, 2023 | 49.9% |